PharmaCyte Biotech Key Fundamental And Technical Indicators

Stocks . USA . 
Stock . PharmaCyte Biotech
PMCB Stock  USD 0.76  -0.04  -5.00%   
Standard valuation, profitability, and solvency ratios for PharmaCyte Biotech are consolidated. PharmaCyte Biotech trades at a price-to-earnings ratio of 9.57. Ratios are most informative when measured against sector medians and historical averages. At present, the 14-period RSI for PharmaCyte Biotech stands at 52, indicating neutral momentum. This neutral positioning leaves PharmaCyte Biotech equally poised for a directional breakout in either direction.
Momentum
OversoldOverbought
52 · Neutral
As of the 8th of May, the last recorded price for PharmaCyte Biotech is 0.76 per share. Primary technical drivers reflect Semi Deviation of 3.96, coefficient of variation of 3718.28, and Risk Adjusted Performance of 0.0339. Quantitative analysis incorporates volatility metrics and price behavior to assess directional bias. Below $1.00, price stability and volume dispersion are closely evaluated. Metrics are compared to industry averages to assess relative positioning.
Cycles Operators Shifting Impulse Patterns Depth Overlaps Statistics Volatility Volume
PharmaCyte Biotech's financial statements serve as the foundation for evaluating earnings quality and balance sheet strength. Key valuation metrics and long-term strategic positioning are highlighted below: Analyzing PharmaCyte Biotech's margins, turnover ratios, and leverage metrics provides a structured basis for estimation. Core indicators are listed below:
 Market Capitalization
8.59 million
 Enterprise Value Revenue
14,270
 Earnings Share
-0.89
There are currently one hundred twenty fundamental measures for PharmaCyte Biotech that can be evaluated and compared over time across peers. Active traders should verify all of PharmaCyte Biotech's latest fundamental drivers against the trend between 2010 and 2026 to make sure the company can sustain itself in the future. In the latest reported period, Market Cap remains stable near $30.89 million. In addition to that, Enterprise Value remains stable near $30.15 million. For wider market screening beyond PharmaCyte Biotech, explore the Equity Screeners module. Peer comparisons and sector-level screening add context beyond individual analysis.
Altman
Z Score
Details
Piotroski
F Score
Details
Beneish
M Score
Details
Profitability
Analysis
Details
Earnings
Projections
Details

Balance Sheet Accounts

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Other Current Liabilities$3.04 million$2.89 million1.4 M
High Variability
Total Current Liabilities$3.52 million$3.35 million1.9 M
High Variability
Common Stock Total Equity$173.71$182.8547.1 K
High Variability
Common Stock Shares Outstanding8.01 million8.43 million302.9 M
High Variability
Total Liabilities$2.42 million$3.77 million2.7 M
High Variability
Common Stock$2,367.45$2,492.0547.8 K
High Variability
Accounts Payable$315,329$459,085305.9 K
High Variability
Total Assets$66.62 million$63.44 million27.8 M
Moderate Growth
Short and Long Term Debt Total$43,438.28$45,724.5213.6 K
High Variability
Other Liabilities$4,370$4,6004.1 K
Stable
Property Plant And Equipment Net$59,475.7$62,60654.7 K
Moderate Growth
Cash$11.99 million$17.45 million15.6 M
High Variability
Non Current Assets Total$39.6 million$37.71 million10.2 M
Moderate Growth
Non Current Assets Other$10.59 million$10.09 million1.9 M
Moderate Growth
Long Term Debt$39,571.11$41,653.862 K
High Variability
Cash And Short Term Investments$12.1 million$17.87 million15.7 M
High Variability
Liabilities And Stockholders Equity$66.62 million$63.44 million27.8 M
Moderate Growth
Inventory$5,853.33$6,161.49.1 K
High Variability
Total Current Assets$12.96 million$25.73 million16.8 M
High Variability
Property Plant Equipment$58,995$62,10054.2 K
Moderate Growth
Net Receivables$4.46 million$4.25 million3.3 M
Moderate Growth
Intangible Assets$3.02 million$1.78 million3 M
High Variability
Good Will$1.69 million$1.9 million2.1 M
Stable
Short Term Debt$43,438.28$45,724.5206.7 K
High Variability
Preferred Stock Total Equity$616,000$667,000582.5 K
Moderate Growth
Net Tangible Assets$104.29 million$99.33 million34.8 M
Moderate Growth
Short and Long Term Debt$24,724.89$26,026.255.5 K
Moderate Decline
Net Invested Capital$33.35 million$59.67 million24.4 M
Moderate Growth
Capital Stock$2,367.45$2,492.05771.3 K
High Variability

Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Other Operating Expenses$5.37 million$5.03 million5.7 M
High Variability
Total Operating Expenses$5.35 million$5.03 million5.7 M
High Variability
Selling General Administrative$4.42 million$4.53 million4.4 M
High Variability
Research Development$636,187$394,574834.5 K
High Variability
Selling And Marketing Expenses$1.04 million$1.52 million1.1 M
High Variability
Non Recurring$485,711$430,807594.4 K
Moderate Decline

Cash Flow Statement Items

Trends
Current ValueLast YearHistorical Average 10 Year Trend
End Period Cash Flow$11.99 million$17.45 million15.6 M
High Variability
Dividends Paid$1.23 million$1.3 million17.4 M
High Variability
Stock Based Compensation$854,905$430,773892.9 K
High Variability
Change To Netincome$96,445.71$101,5226.9 M
Moderate Decline

Financial Ratios

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio3,348.08x3,188.64x3.2 K
High Variability
Dividend Yield12.00%11.00%0.116
High Variability
Days Sales Outstanding15.4616.2813.9708
Moderate Growth
Average Payables$219,082$354,858320.3 K
High Variability
Stock Based Compensation To Revenue0.06x0.07x0.0796
Stable
Capex To Depreciation$0.15$0.160.1745
Moderate Decline
EV To Sales3,365.23x3,204.98x3.2 K
High Variability
Inventory Turnover2.422.552.625
High Variability
Days Of Inventory On Hand140.84148.251.4 K
High Variability
Payables Turnover0.030.030.0355
High Variability
Sales General And Administrative To Revenue100.1x95.33x83.3024
High Variability
Average Inventory$51,138.83$53,830.3556.8 K
Moderate Variation
Research And Ddevelopement To Revenue0.08x0.08x34.8505
High Variability
Capex To Revenue0.01x0.01x1.1182
High Variability
Cash Per Share4.592.443.2543
High Variability
Days Payables Outstanding10,573.8415,358.6612.6 K
High Variability
Intangibles To Total Assets$0.03$0.030.301
Moderate Decline
Current Ratio8.398.8347.1554
High Variability
Receivables Turnover18.7323.2126.5267
Moderate Variation
Graham Number$24.39$23.235.8001
Moderate Growth
Average Receivables$1,409.87$1,484.078.1 K
High Variability
Revenue Per Share0.050.050.055
High Variability
Interest-Bearing Debt Per Share000.9888
Moderate Decline
Debt To Assets0.01x0.01x0.1836
Moderate Decline
Operating Cycle$156.3$164.531.4 K
High Variability
Days Of Payables Outstanding10,573.8415,358.6612.6 K
High Variability
Long Term Debt To Capitalization0.01x0.01x0.1198
High Variability
Quick Ratio8.398.8336.4976
High Variability
Net Income Per EBT$1.3$1.151.1267
High Variability
Cash Ratio5.695.9935.8075
High Variability
Days Of Inventory Outstanding140.84148.251.4 K
High Variability
Days Of Sales Outstanding15.4616.2813.9708
Moderate Growth
Free Cash Flow Operating Cash Flow Ratio3.062.923.079
Moderate Variation
Fixed Asset Turnover2.532.662.2144
High Variability
Debt Ratio0.010.010.1836
Moderate Decline
Price Sales Ratio3,348.08x3,188.64x3.2 K
High Variability
Asset Turnover000.0065
High Variability
Gross Profit Margin23.00%24.00%0.2686
High Variability

Valuation Indicators

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Market Cap$29.34 million$30.89 million49.2 M
High Variability
Enterprise Value$29.05 million$30.15 million48.2 M
High Variability

Core Fundamental Drivers

Forward Price Earnings7.0175
Cash And Short Term Investments15.54 million

Return On Equity TTM Driver Correlations

The correlation structure highlights which of PharmaCyte Biotech's financial accounts move most closely with changes in Return On Equity TTM. Accounts with strong positive correlation tend to respond to the same operating conditions at PharmaCyte Biotech.
Click cells to compare fundamentals
Competition

PharmaCyte Accumulated Other Comprehensive Income

Accumulated Other Comprehensive Income

-28,822
Accumulated Other Comprehensive Income stood at $-27,449.35 as of December 31, 2025.

PharmaCyte Biotech Fundamental Drivers Relationships

ROE stood at 1.06 as of December 31, 2025. Related reported metric: Return On Asset TTM at 53.00% as of December 31, 2025.

Main Technical Indicators as of May 8, 2026

Cycle Indicators
Math Operators
Math Transform
Momentum Indicators
Overlap Studies
Pattern Recognition
Price Transform
Statistic Functions
Volatility Indicators
Volume Indicators
Risk Adjusted Performance0.0339
Market Risk Adjusted Performance1.61
Mean Deviation3.52
Semi Deviation3.96
Downside Deviation4.64
Coefficient Of Variation3718.28
Standard Deviation4.7
Variance22.11
Information Ratio0.0252
Jensen Alpha0.1166
Total Risk Alpha0.1269
Sortino Ratio0.0256
Treynor Ratio1.6
Maximum Drawdown24.36
Value At Risk-7.69
Potential Upside8.33
Downside Variance21.5
Semi Variance15.71
Expected Short fall-4.43
Skewness0.5231
Kurtosis1.14

Daily Market Strength Indicators

Market strength indicators for PharmaCyte Biotech quantify how the stock responds to shifts in volume and sentiment. These indicators capture shifts in momentum that may precede significant price moves in PharmaCyte Biotech. The Market Facilitation Index measures how efficiently price moves relative to volume — rising MFI with rising volume signals strong trend participation. Monitoring these indicators for PharmaCyte Biotech through complete market cycles reveals recurring patterns.
Accumulation Distribution4269.15
Daily Balance Of Power-0.67
Rate Of Daily Change0.95
Day Median Price0.77
Day Typical Price0.77
Price Action Indicator-0.03
Period Momentum Indicator-0.04
Relative Strength Index52.38

Basic Forecasting Models

Bollinger Bands applied to PharmaCyte Stock price data measure how far PharmaCyte has deviated from its recent average relative to its own volatility. This distinction drives the choice of forecasting model applied to PharmaCyte Biotech's price data. On-balance volume for PharmaCyte Stock creates a running indicator of buying versus selling pressure in PharmaCyte. Price departures from the channel boundary often mean-revert, offering tactical signals for PharmaCyte Biotech's.
Naive Prediction
Simple Exponential Smoothing
Double Exponential Smoothing
Triple Exponential Smoothing
Simple Regression
Polynomial Regression
Simple Moving Average
4 Period Moving Average
8 Period Moving Average
20 Period Moving Average

PharmaCyte Biotech Related Equities

These stocks are related to PharmaCyte Biotech within the Health Care space and can be used for peer review, pricing, or spreading risk. Growth rate gaps between PharmaCyte Biotech and its peers often explain pricing differences in the market. Persistent outperformance or underperformance by specific peers relative to PharmaCyte Biotech often signals structural advantages or weaknesses.
 Risk & Return  Correlation

Return On Equity TTM Peer Comparison

Peer-based analysis of PharmaCyte Biotech on Return On Equity TTM allows investors to benchmark performance against similar stocks. A favorable PharmaCyte Biotech's Return On Equity TTM compared to competitors can indicate undervaluation or a stronger fundamental position. Outlier Return On Equity TTM values among PharmaCyte Biotech peers often point to structural differences in business models. This analysis benchmarks PharmaCyte Biotech against the most relevant set of comparable stocks.
PharmaCyte Biotech is currently under evaluation in return on equity ttm among leading competitors.

Important Fundamentals

Return On Equity TTM-0.0824
Return On Asset TTM-0.0675
Current Valuation-11.8 M
Shares Outstanding10.74 M
Shares Owned By Insiders5.74 %
Shares Owned By Institutions9.38 %
Number Of Shares Shorted84.83 K
Price To Earnings TTM9.57 X
Price To Book TTM0.20 X
Price To Sales TTM12,904 X
EBITDA TTM30.66 M
Net Income TTM30.66 M
Cash And Equivalents TTM82.23 M
Cash Per Share TTM3.96 X
Total Debt TTM3.28 M
Current Ratio TTM75.51 X
Book Value Per Share TTM3.59 X
Cash Flow From Operations TTM-2.98 M
Short Ratio TTM0.49 X
Earnings Per Share-0.89 X
Trailing Beta0.46
Market Capitalization TTM8.59 M
Total Asset TTM55.17 M
Retained Earnings TTM-84.97 M
Working Capital TTM19.46 M
Current Asset TTM1.6 M
Current Liabilities TTM449 K
Net Asset55.17 M

Financial Metrics, Fundamentals & Methodology

PharmaCyte Biotech is best assessed through earnings quality, cash generation, and balance-sheet capacity. Cash-flow trends help test whether reported earnings are being backed by real operating performance. For the latest reporting period, PharmaCyte Biotech reports EPS loss of 0.89, current ratio of 75.51.

PharmaCyte Biotech data is compiled from periodic company reporting and market reference feeds and standardized for comparability. Financial statement fields are presented under issuer-reported GAAP or IFRS accounting conventions.

Editorial review and methodology oversight provided by: Gabriel Shpitalnik, Member of Macroaxis Editorial Board


 
Tools
Analysis
Directory
Company
2026 Macroaxis LLC Made with in San Francisco
Privacy Terms Widgets Feedback
Macroaxis is not a registered investment advisor or broker/dealer. All investments, including stocks, funds, ETFs, or cryptocurrencies, are speculative and involve substantial risk of loss. We encourage our investors to invest carefully. Much of our information is derived directly from data published by companies or submitted to governmental agencies which we believe are reliable, but are without our independent verification. Therefore, we cannot assure you that the information is accurate or complete. We do not in any way warrant or guarantee the success of any action you take in reliance on our statements or recommendations. Also, note that past performance is not necessarily indicative of future results. All investments carry risk, and all investment decisions of an individual remain the responsibility of that individual. There is no guarantee that systems, indicators, or signals will result in profits or that they will not result in losses. All investors are advised to fully understand all risks associated with any investing they choose to do. Hypothetical or simulated performance is not indicative of future results. We make no representations or warranties that any investor will, or is likely to, achieve profits similar to those shown because hypothetical or simulated performance is not necessarily indicative of future results. For more information please visit our terms and conditions page.